Empagliflozin is under clinical development by Boehringer Ingelheim International and currently in Phase II for Glycogen Storage Disorders (GSD). According to GlobalData, Phase II drugs for Glycogen Storage Disorders (GSD) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Empagliflozin LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Empagliflozin (Jardiance, BI 10773, Gibtulio, Jardianz) is an anti-diabetic drug, belongs to the class of blood glucose lowering drugs. It is formulated as coated tablets and film-coated tablets for oral route of administration. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also indicated as an adjunct to diet, exercise and standard care therapy, to reduce the incidence of cardiovascular (CV) death in patients with type 2 diabetes and established CV disease who have inadequate glycemic control. Jardiance also indicated to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease. Jardiance is indicated in adults, as an adjunct to standard of care therapy, for the treatment of patients with heart failure with reduced ejection fraction. Jardiance is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults. Jardiance (empagliflozin) is indicated for the treatment of symptomatic chronic heart failure with preserved ejection fraction (HFpEF) in adults. Jardiance is indicated in adults as an adjunct to standard of care therapy for the treatment of chronic heart failure.
The drug candidate is under development for the treatment of glycogen storage disease type 1b and type 2, postprandial hypoglycemia, pulmonary arterial hypertension and kidney stones. It is a new chemical entity. It is also under development for cardiovascular outcomes in chronic heart failure with reduced and preserved ejection fraction (Systolic and Diastolic heart failure), acute heart failure, acute myocardial infarction, acute decompensated heart failure and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and chronic kidney disease.
The drug candidate was under development for the treatment of type 1 diabetes.
Boehringer Ingelheim International overview
Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for swine, ruminant, poultry, horses and pets among others. Boehringer is headquartered in Ingelheim, Rheinland-Pfalz, Germany.
For a complete picture of Empagliflozin’s drug-specific PTSR and LoA scores, buy the report here.